48,718 Shares in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Bought by Hsbc Holdings PLC

Hsbc Holdings PLC bought a new position in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDXFree Report) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 48,718 shares of the company’s stock, valued at approximately $1,053,000. Hsbc Holdings PLC owned 0.06% of Syndax Pharmaceuticals at the end of the most recent reporting period.

Other institutional investors have also recently bought and sold shares of the company. Principal Financial Group Inc. increased its holdings in shares of Syndax Pharmaceuticals by 27.8% during the 3rd quarter. Principal Financial Group Inc. now owns 43,120 shares of the company’s stock worth $626,000 after purchasing an additional 9,371 shares during the period. New York State Common Retirement Fund increased its holdings in shares of Syndax Pharmaceuticals by 3.6% during the 3rd quarter. New York State Common Retirement Fund now owns 30,825 shares of the company’s stock worth $448,000 after purchasing an additional 1,080 shares during the period. Quantbot Technologies LP bought a new position in shares of Syndax Pharmaceuticals during the 3rd quarter worth about $131,000. Swiss National Bank increased its holdings in shares of Syndax Pharmaceuticals by 1.4% during the 3rd quarter. Swiss National Bank now owns 121,000 shares of the company’s stock worth $1,757,000 after purchasing an additional 1,700 shares during the period. Finally, Charles Schwab Investment Management Inc. increased its holdings in shares of Syndax Pharmaceuticals by 3.1% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 506,467 shares of the company’s stock worth $7,354,000 after purchasing an additional 15,156 shares during the period.

Analyst Upgrades and Downgrades

SNDX has been the topic of several research reports. JPMorgan Chase & Co. restated an “overweight” rating and set a $34.00 price objective on shares of Syndax Pharmaceuticals in a report on Tuesday, May 21st. Citigroup lowered their target price on shares of Syndax Pharmaceuticals from $32.00 to $30.00 and set a “buy” rating on the stock in a research note on Thursday, May 9th. HC Wainwright reissued a “buy” rating and issued a $41.00 target price on shares of Syndax Pharmaceuticals in a research note on Thursday. Finally, Stifel Nicolaus upped their target price on shares of Syndax Pharmaceuticals from $39.00 to $40.00 and gave the company a “buy” rating in a research note on Thursday, May 9th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and ten have issued a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $34.42.

Check Out Our Latest Report on Syndax Pharmaceuticals

Syndax Pharmaceuticals Stock Up 0.5 %

NASDAQ:SNDX opened at $19.50 on Monday. The firm has a market cap of $1.66 billion, a PE ratio of -6.06 and a beta of 1.01. Syndax Pharmaceuticals, Inc. has a 12 month low of $11.22 and a 12 month high of $25.34. The company’s 50-day moving average price is $21.21 and its two-hundred day moving average price is $21.19.

Syndax Pharmaceuticals (NASDAQ:SNDXGet Free Report) last released its quarterly earnings results on Wednesday, May 8th. The company reported ($0.85) EPS for the quarter, beating analysts’ consensus estimates of ($0.96) by $0.11. During the same quarter last year, the business earned ($0.59) earnings per share. On average, research analysts expect that Syndax Pharmaceuticals, Inc. will post -3.57 EPS for the current fiscal year.

About Syndax Pharmaceuticals

(Free Report)

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).

Further Reading

Institutional Ownership by Quarter for Syndax Pharmaceuticals (NASDAQ:SNDX)

Receive News & Ratings for Syndax Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syndax Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.